These limitations have brought about innovations to enhance the bio-delivery of NGF for AD therapy by using stem cells, viral vectors, small molecule modulators and most recently, encapsulated cell biodelivery (ECB) [233]. This evidence concerns the gene NGF and Alzheimer disease.